Date: 2011-12-12
Type of information: Initiation of preclinical development
phase: preclinical
Announcement: initiation of preclinical development
Company: Ablynx (Belgium) Merck Serono (Germany)
Product: ALX-0761
Action
mechanism: Nanobodies are antibody-derived therapeutic proteins that contain the unique structural and functional properties of naturally-occurring heavy-chain antibodies. ATN-103 and PF-05230905 are both anti-TNF alpha Nanobodies.
Disease: autoimmune diseases
Therapeutic area: Autoimmune diseases
Country:
Trial details:
Latest
news: * On December 12, 2011, Ablynx and partner Merck Serono announced that they have advanced the Nanobody candidate, ALX-0761, into pre-clinical development for the treatment of autoimmune diseases. This is the first pre-clinical candidate that has emerged from the collaboration which the companies entered in 2008, and will result in a €1 million milestone payment to Ablynx.
